Skip to main content
. 2020 Dec 30;22(1):306. doi: 10.3390/ijms22010306

Figure 2.

Figure 2

Cadherins in wild-type and mutant muscle cell precursors. (A). Confocal immunofluorescence images of F-actin (phalloidin, red) and cadherin (white or green) in WT (WT1 and WT2) and LMNA-CMD mutant (ΔK32, L380S and R249W) muscle cell precursors. Nuclei are stained with Hoechst (blue). Scale bar: 20 µm. Zoomed region of cell-cell junctions are shown in left panels. Scale bar: 10 µm. (B). Top: Representative Western blot of M-cadherin and GAPDH expression in WT and LMNA mutant myoblasts. Bottom: Quantification of M-cadherin protein levels normalized to GAPDH and expressed as fold change versus WT. Values are means ± SEM, n ≥ 3 from at least 2 separate experiments. * p < 0.005 compared with WT. (C) Top: Representative Western blot M-cadherin and α-tubulin expression in WT and R249W myoblasts after 4h-treatment with cyclohexamide (CHX). Bottom: Percentage fold-change in M-cadherin protein levels in WT and mutant myoblasts after CHX treatment. M-cadherin protein levels normalized to β-tubulin. Pooled values of WT (WT1 and WT2) are presented. Values are means ± SEM, n = 3 in WT and mutant cell lines. * p < 0.05 compared with WT. (D) mRNA expression of CDH15 normalized to RPLP0 and expressed as fold-changes vs WT. Pooled values of WT (WT1 and WT2) are presented. Values are means ± SEM, n = 3 separate experiments. There was no significant difference between cell lines.